GRAIL, Inc. (GRAL)
140.58
+3.21
(+2.34%)
USD |
NASDAQ |
Oct 13, 14:53
GRAIL Enterprise Value : 5.365B for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 5.365B |
| October 09, 2026 | 5.509B |
| October 08, 2026 | 5.153B |
| October 07, 2026 | 5.166B |
| October 06, 2026 | 5.361B |
| October 05, 2026 | 6.112B |
| October 02, 2026 | 5.629B |
| October 01, 2026 | 5.151B |
| September 30, 2026 | 5.488B |
| September 29, 2026 | 5.330B |
| September 28, 2026 | 5.154B |
| September 25, 2026 | 4.897B |
| September 24, 2026 | 4.822B |
| September 23, 2026 | 4.077B |
| September 22, 2026 | 4.077B |
| September 21, 2026 | 4.052B |
| September 18, 2026 | 2.837B |
| September 17, 2026 | 2.801B |
| September 16, 2026 | 2.585B |
| September 15, 2026 | 2.619B |
| September 14, 2026 | 2.603B |
| September 11, 2026 | 2.635B |
| September 10, 2026 | 2.694B |
| September 09, 2026 | 2.690B |
| September 08, 2026 | 2.763B |
| Date | Value |
|---|---|
| September 04, 2026 | 2.818B |
| September 03, 2026 | 2.831B |
| September 02, 2026 | 2.828B |
| September 01, 2026 | 2.794B |
| August 31, 2026 | 2.775B |
| August 28, 2026 | 2.803B |
| August 27, 2026 | 2.915B |
| August 26, 2026 | 2.785B |
| August 25, 2026 | 2.916B |
| August 24, 2026 | 2.650B |
| August 21, 2026 | 2.782B |
| August 20, 2026 | 2.712B |
| August 19, 2026 | 2.533B |
| August 18, 2026 | 2.396B |
| August 17, 2026 | 2.354B |
| August 14, 2026 | 2.261B |
| August 13, 2026 | 2.278B |
| August 12, 2026 | 2.309B |
| August 11, 2026 | 2.601B |
| August 10, 2026 | 2.573B |
| August 07, 2026 | 2.333B |
| August 06, 2026 | 2.062B |
| August 05, 2026 | 2.543B |
| August 04, 2026 | 2.477B |
| August 03, 2026 | 2.368B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 81.43B |
| Twist Bioscience Corp. | 9.444B |
| Prime Medicine, Inc. | 669.87M |
| Kailera Therapeutics, Inc. | 562.07M |
| Arrowhead Pharmaceuticals, Inc. | 8.346B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -110.25M |
| Revenue (Quarterly) | 44.69M |
| Total Expenses (Quarterly) | 154.93M |
| EPS Diluted (Quarterly) | -2.557 |
| Gross Profit Margin (Quarterly) | -30.61% |
| Profit Margin (Quarterly) | -246.7% |
| Earnings Yield | -6.93% |
| Normalized Earnings Yield | -6.641 |